• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } Policy

Larry Goldstein, a well-known stem cell researcher at the University of California, San Diego who has received nearly $22 million in awards from the California stem cell agency, today was named to its governing board. It was the first time in the history of the 16-year-old agency that a scientist who has received agency awards has been appointed to the…

2021 01 15 Biotech (General)
Stem Cells

DEA Removes CBD from Controlled Substances Act

On Monday, April 6, GW Pharmaceuticals revealed that the company had received notice from the U.S. Drug Enforcement Administration (“DEA”) stating that its drug Epidiolex was no longer subject to the requirements of the Controlled Substances Act (“CSA”). In a company release announcing the agency decision, GW CEO Justin Gover stated, “This notification from DEA fully establishes…

2020 04 17 Biotech (General)
Biotech Stocks To Watch

Major cancer institute sued by its own researchers over ‘tapering’ funding

Alleging that a leading cancer funder is slashing their support in an “unethical and reckless” way, six prominent cancer researchers at the University of California, San Diego (UCSD), have filed a lawsuit to compel it to continue its current level of support. The suit, filed quietly in November 2019 and amended last week, contends that the…

2020 02 08 Biotech (General)
Corporate News
Other

Democrats sink House vote on Trump-backed drug bill

House Republicans failed Tuesday evening to pass a “right-to-try” bill that would give terminally ill patients access to experimental drugs without FDA authorization after failing to muster enough votes to approve it through an expedited process. The 259-140 vote fell short of the necessary two-thirds support from the House chamber. The failed vote is a…

2018 03 14 Biotech (General)
Clinical Trials